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DNA Adducts of Decarbamoyl Mitomycin C Efficiently Kill Cells
without Wild-Type p53 Resulting from Proteasome-Mediated
Degradation of Checkpoint Protein 1
Ernest K. Boamah,†,| Angelika Brekman,† Maria Tomasz,‡ Natura Myeku,†
Maria Figueiredo-Pereira,† Senyene Hunter,§ Joel Meyer,§ Rahul C. Bhosle,† and
Jill Bargonetti*,†
Department of Biological Sciences, and Department of Chemistry, Hunter College and The Graduate Center,
CUNY, 695 Park AVenue, New York, New York 10065, and Nicholas School of the EnVironment, Duke
UniVersity, Durham, North Carolina 27708
ReceiVed NoVember 24, 2009

The mitomycin derivative 10-decarbamoyl mitomycin C (DMC) more rapidly activates a p53independent cell death pathway than mitomycin C (MC). We recently documented that an increased
proportion of mitosene1-β-adduct formation occurs in human cells treated with DMC in comparison to
those treated with MC. Here, we compare the cellular and molecular response of human cancer cells
treated with MC and DMC. We find the increase in mitosene 1-β-adduct formation correlates with a
condensed nuclear morphology and increased cytotoxicity in human cancer cells with or without p53.
DMC caused more DNA damage than MC in the nuclear and mitochondrial genomes. Checkpoint 1
protein (Chk1) was depleted following DMC, and the depletion of Chk1 by DMC was achieved through
the ubiquitin proteasome pathway since chemical inhibition of the proteasome protected against Chk1
depletion. Gene silencing of Chk1 by siRNA increased the cytotoxicity of MC. DMC treatment caused
a decrease in the level of total ubiquitinated proteins without increasing proteasome activity, suggesting
that DMC mediated DNA adducts facilitate signal transduction to a pathway targeting cellular proteins
for proteolysis. Thus, the mitosene-1-β stereoisomeric DNA adducts produced by the DMC signal for a
p53-independent mode of cell death correlated with reduced nuclear size, persistent DNA damage, increased
ubiquitin proteolysis and reduced Chk1 protein.
Introduction
The p53 protein is an important tumor suppressor and is
frequently mutated in cancer cells (1, 2). DNA damage activates
and stabilizes wild-type p53, which results in increased transcription of multiple p53 target genes involved in cell cycle
arrest or apoptotic cell death (3, 4). It has been estimated that
over 50% of all cancers harbor a mutation in the p53 gene, and
this interferes with the ability of the protein to effectively induce
cell death (1). Loss of p53 function has been associated with
increased resistance to chemotherapeutic agents (5). In addition,
loss of p53 or its downstream target, p21, disrupts the G1/S
checkpoint in response to DNA damage (6, 7). Lack of a G1/S
checkpoint causes cells to depend entirely on their intra-S and
G2/M checkpoints to ensure genomic integrity (8).
The ataxia-telangiectasia and Rad3-related (ATR1) and
Checkpoint protein 1 (Chk1) pathways regulate genome fidelity
* To whom correspondence should be addressed. E-mail: bargonetti@
genectr.hunter.cuny.edu.
†
Department of Biological Sciences.
‡
Department of Chemistry, Hunter College and The Graduate Center,
CUNY, 695 Park Ave., NY, NY 10065.
§
Duke University.
|
Current address: Epigenetics and Progenitor Cells Program, Fox Chase
Cancer Center, 333 Cottman Ave., R362, Philadelphia, PA 19111.
1
Abbreviations: ATR, ataxia-telangiectasia and Rad3-related; Chk1,
Checkpoint 1; Chk2, Checkpoint 2; ATM, ataxia telangiectasia mutated;
MC, mitomycin C; DMC, decarbamoyl mitomycin C; MTT, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; FBS, fetal bovine
serum; G418, gentamycin; DAPI, 4′,6-diamidino-2-phenylindole; RT-PCR,
reverse transcriptase-polymerase chain reaction; anti-BPDE, anti-7,8dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene.

at the G2/M transition and are especially important to cells
lacking a functional p53 checkpoint pathway (9, 10). The
phosphatidylinositol 3-kinase-related kinase ATR, a DNA
damage and replication stress response protein, is part of a
complex network of checkpoint proteins which are activated in
response to deleterious lesions that affect replication fork
progression (9, 11). In response to DNA interstrand cross-links
and other DNA lesions, ATR phosphorylates Chk1 on two
critical residues, Ser-317 and Ser-345 (12, 13). When activated,
Chk1 delays entry into mitosis by phosphorylating and inactivating Cdc25A and Cdc25C, two phosphatases required for cell
cycle progression (14). DNA damage recognition activities of
the Fanconi anemia core complex cooperate with ATR to signal
for interstrand cross-link repair and Chk1 phosphorylation
(15-17). In the absence of Chk1, cells with DNA damage
continue through mitosis culminating in cell death by mitotic
catastrophe due to the lack of a G2/M checkpoint (18-20).
Disruption of the Chk1 G2/M checkpoint kinase is a provocative
death target, especially for cells with compromised p53 since
these cells lack an efficient G1/S checkpoint (21-24).
Mitomycin C (MC), a bioreductive DNA alkylating agent,
is a well-known antitumor, antibiotic, and chemotherapeutic
agent (25-27). Within the intracellular compartment, MC is
metabolized by reductive enzymes to generate reactive DNA
alkylating species and oxygen radicals through redox cycling
(26). Activated MC alkylates guanine at the N2-position to form
DNA monoadducts and DNA intrastrand and interstrand crosslink adducts (28). 10-Decarbamoyl mitomycin C (DMC), a
derivative of MC, has also been shown to bind DNA forming
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Figure 1. Chemical structures of DNA adducts: 1a, 1′′-R MC monoadduct; 2a, 1-′′R DMC monoadduct; 2b, 1′′-β DMC monoadduct; 3a, 1′′-R
interstrand cross-link; 3b, 1′′-β interstrand cross-link.

a similar but not identical array of DNA adducts (29, 30). We
recently demonstrated that equimolar concentrations of DMC
produce more DNA adducts in human cells than MC, and most
of the adducts have altered stereochemistry (30). Specifically,
the chirality of the mitosene linkage of MC to guanine-N2 of
DNA is opposite of that of DMC (mitosene-1-R vs mitosene1-β) (Figure 1). The critical cytotoxic lesion produced by
chemotherapeutic DNA damaging agents such as mitomycin C
has been proposed to be the interstrand cross-link adducts
(31, 32). These interstrand cross-link DNA modifications, in
part, inhibit strand separation during replication and transcription, which in turn activates ATR and ataxia telangiectasia
mutated (ATM) checkpoint pathways (10). Although both MC
and DMC produce these cross-link DNA adducts, interestingly,
DMC induces death of cells more rapidly than MC (29, 33, 34).
We previously reported that DMC induces the death of many
different cell types more rapidly than MC both in the presence
and absence of wild-type p53 (33, 34). We hypothesized that
this difference in cytotoxicity may be based on differential
signaling of DNA adducts of MC and DMC. The recent
investigation of the nature of the cell death pathways induced
by the two drugs suggested that the Chk1 pathway might be
involved in differential cytotoxicity (33). Moreover, we documented more DNA adduct formation following the treatment

of multiple different types of human cancer cells with DMC
than with MC (30). The rationale of the present study was to
determine whether the mitomycin analogue DMC might be
useful for clinical development for cancers that lack wild-type
p53 because at equimolar concentrations, DMC is more cytotoxic to p53-deficient cells than MC and thus could be used at
lower concentrations to induce cell death. We compared the
amount and persistence of the DNA damage induced by the
two drugs and compared the cellular and molecular responses
of human cancer cells with and without wild-type p53 treated
with MC and DMC. We then focused our studies on cells
without wild-type p53 (DLD-1) and correlated the DMC induced
depletion of the G2 checkpoint control protein Chk1 with
increased cell death and characterized the involvement of the
ubiquitin proteolysis pathway in the Chk1 depletion.

Materials and Methods
Caution: The mitomycins are hazardous chemicals and should
be handled carefully.
Materials. Mitomycin C was obtained from Bristol-Myers
Squibb Co., Wallingford, CT and from Kyowa Hakko Kogyo Co.
Ltd., Japan. The procedure used for the synthesis of 10-decarbamoyl
mitomycin C was as described previously (35). Growth medium
and penicillin-streptomycin solution were obtained from Mediatech

DNA Adducts Cause Chk1 Depletion by Proteasome
Inc., Herndon, VA and fetal bovine serum (FBS) and Gentamycin
(G418) were purchased from Gemini Bio-Products, West Sacramento, CA. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), and MG115 (2-LLnVal) were purchased from
Sigma, Allentown, PA. Hygromycin B was purchased from
Calbiochem, La Jolla, CA.
Cell Culture, Drugs, and Plasmids. MCF-7 human breast cancer
cells (wild-type p53), obtained from American Type Culture
Collection, were grown in 90% RPMI/10% fetal bovine serum and
penicillin (50 units/mL)-streptomycin (50 µg/mL) solution. The
isogenic colon cancer cell lines used were the well characterized
DLD-1 and DA-2 lines; they were a generous gift from Bert
Vogelstein (Johns Hopkins School of Medicine), whose group used
a two-step procedure to establish a tetracycline-off system for
controlled wild-type p53 expression in DA-2 cells (36). DLD-1
cells do not express wild-type p53, and DA-2 cells maintained in
the presence of doxycycline express a trace amount of wild-type
p53. DLD-1 cells were grown in 90% McCoys/10% fetal bovine
serum and penicillin (50 units/ml)-streptomycin (50 µg/mL)
solution, while DA-2 cells were maintained in an additional 0.4
mg/mL G418, 20 ng/mL doxycycline, and 0.25 mg/mL Hygromycin
B. All cell culture experiments were carried out at 37 °C in an
atmosphere of 95% air/5% CO2. MC and DMC were dissolved in
30% methanol/70% water. The pCS3+-6Myc plasmid expressing
Myc-Chk1 protein was kindly provided by You-Wei Zhang (Salk
Institute, La Jolla, CA).
Quantitative PCR-Based Measurement of Nuclear and
Mitochondrial DNA Damage. Comparative quantitation of mitochondrial and nuclear genome DNA damage was carried out by
quantitative PCR (QPCR) as previously described (37-39). Briefly,
MCF-7 cells were treated for 1 h with either MC or DMC (10 µM).
Following incubation, cells were washed 2× with Hanks buffer
and either immediately harvested or allowed to recover in fresh
media for 12 h at 37 °C. DNA was isolated from treated and
untreated cells and subjected to QPCR for the measurement of
nuclear and mitochondrial DNA damage and repair. This assay
functions by quantifying the degree of inhibition of PCR amplification observed in damaged samples, compared to control samples,
that results from the presence of DNA lesions that block or inhibit
the progression of DNA polymerase. Thus, the QPCR assay has
the advantage of measuring all polymerase-blocking lesions
but the disadvantage of not identifying the nature of the DNA
damage. Large portions of the mitochondrial and nuclear genomes
were amplified using specific primers. Specifically, primers 2372
and 3927 were used to amplify a 12.2-kb portion of the DNA
polymerase β gene, and primers 14841 and 5999 were used to
amplify an 8.9-kb portion of the mitochondrial genome, which
encompasses roughly 50% of the mitochondrial genome (and thus
many genes). Additionally, a small fragment (221 bp) of the
mitochondrial genome was amplified using primers 14841 and
14620 (amplifying a small region of the DNA polymerase β gene),
and used to monitor the mtDNA copy number as well as to
normalize the results obtained from the large mitochondrial
fragment. All primer sequences as well as QPCR assay conditions
were as indicated by Santos et al. (38) Amplifications of treated
controls were compared to those of untreated controls to calculate
the relative amplification and determine the lesion frequency in
treated samples above the basal levels in nontreated controls. Results
presented are the mean of at least two sets of PCRs for each
amplicon for each sample; n ) 3 per sample.
Quantitative Reverse Transcription-PCR. RNA was isolated
using the Qiagen RNeasy mini kit. Five micrograms of RNA was
used for cDNA synthesis using the high capacity cDNA archive
kit (Applied Biosystems). The primer-probes for chk1, p21, and
mdm2 (Applied Biosystems, Celera Discovery Systems Assays on
Demand) and actin (Applied Biosystems Predeveloped Assay
Reagents) were utilized for Taqman PCR using the Applied
Biosystems 7500 sequence detection system (Perkin-Elmer) as
follows: one cycle, 2 min (50 °C); one cycle, 10 min (94 °C); and
40 cycles, 15 s (94 °C) and 1 min (60 °C).
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RNA Interference and Transfections. For siRNA experiments,
cells were seeded at 60% confluence in media without penicillinstreptomycin and allowed to attach overnight. Cells were transfected
with 25 nM of each of the specified siRNA (all from Dharmacon)
for 24 h using Lipofectamine 2000 (Invitrogen). At the end of the
incubation period, fresh media without penicillin-streptomycin was
added to cells for 2 h, after which cells were either left untreated
or treated with 10 µM MC or 10 µM DMC for an additional 24 h.
Protein extracts were obtained from cells for Western blot analysis.
For 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) analysis, after siRNA transfections, cells were incubated
for an additional 2 h with MTT solution and analyzed for
proliferation.
For overexpression experiments, cells were plated at 90%
confluence and transfected with 4 µg of each indicated plasmid for
24 h using Lipofectamine 2000. Cells were then either left untreated
or treated with 10 µM MC or 10 µM DMC for an additional 24 h
followed by protein extraction or MTT analysis for proliferation.
Flow Cytometry and MTT analysis. FACS analysis was carried
out on a BD Biosciences FACS scan. Cells were washed twice
with phosphate-buffered saline (PBS) containing 2% bovine serum
albumin and 0.1% NaN3. Cells were then fixed in 30% ethanol.
Propidium iodide staining and RNase treatment were carried out
at 37 °C. The viabilities of the cell lines following treatment with
DNA damaging agents were determined using the tetrazolium dyebased microtitration assay as described (33).
Protein Extract Preparation. Briefly, at the end of the incubation period, cells were harvested, washed 2× in ice-cold PBS at
pH 7.5, and spun down after each wash at 300g. Cell pellets were
dissolved in RIPA buffer (0.1% w/v SDS, 0.5% w/v deoxycholate,
150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM tris at pH
8.0, 1 mM PMSF, 20 µM aprotonin, and 20 µM leupeptin and
supplemented with phosphatase inhibitor cocktail (Sigma) as
suggested by the manufacturer) and incubated on ice for 10 min
with periodic shaking. Pellets were then centrifuged at 9,300g for
15 min. The supernatants were collected and kept at -80 °C for
future analysis.
Western Blot Analysis. Protein samples were size-fractionated
by electrophoresis in 10% SDS denaturing poly acrylamide gels
and electrotransferred to nitrocellulose membranes (Amersham).
For ubiquitinated products, samples were separated on a 10%
and 8% (bottom and top, respectively) denaturing gel prior to
transfer. The resulting blots were incubated with the following
primary antibodies: p53 specific monoclonal antibodies [1:1:1
mixture of 421, 240, and 1801 antibodies) as described (40, 41)],
anti-Chk1 (Santa Cruz Biotech., cat. no. sc-7898), antiubiquitin
(Dako, cat. no. Z0458), antiproteasome (Biomol, anti-β5 cat. no.
PW8895), antimyc (Santa Cruz Biotech., cat. no. sc-40), and the
polyclonal antiactin antibody (Sigma). The membranes were then
incubated in antimouse or antirabbit secondary antibodies (Sigma),
and the signals were visualized by chemiluminescence. Densitometry analysis was performed using NIH imageJ, and values were
normalized to actin.
Confocal Microscopy. After drug treatment, cells were fixed
with 2% paraformaldehyde in PBS for 15 min at room temperature.
Cells were permeabilized with PBS containing 0.2% triton x-100
v/v and 1% fetal bovine serun v/v for 5 min at -20 °C and washed
3× in 1% FBS-PBS. Coverslips were immediately mounted onto
slides with 4′, 6′-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc.). Nuclear morphology was visualized using spinning
disk confocal microscopy. All images were captured using a 100×
objective. NIH imageJ was used to determine nuclear size.
Proteasome Activity Assay. Native gel proteasome assays were
carried out as described previously (42). Briefly, cells were washed
2× in PBS and lysed in buffer A (50 mM Tris-HCL pH 7.4, 5 mM
MgCl2, 5 mM ATP, 1 mM DTT, and 10% glycerol v/v). Extracts
were homogenized on ice and spun down at 4 °C for 15 min at
15,000g. Thirty micrograms of proteins were analyzed on a
nondenaturing gradient PAGE gel (5, 4, and 3% from bottom up)
with Rhinohide polyacrylamide strengthener (Molecular Probes).
Gels were then covered with 0.4 mM of the proteasome substrate,
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Table 1. Comparison of the Frequencies of MC- and DMCAdducts in MCF-7 Cellsa

drug
MCb
DMCb

3a
3b
1a
2a
2b
interstrand interstrand
monoadduct monoadduct monoadduct cross-link cross-link
1.9

mol adduct/mol DNA nucleotide (×10-7)
14
1.5
9.3
97
148
1.5

4.6
27

a
MCF-7 cells were left untreated or treated for 24 h with 10 µM MC
or 10 µM DMC. After treatments, DNA was isolated from the MCF-7
cells and digested to nucleosides. Data represent three independent
injections of DNA adducts from the same experiment (30). b From data
in ref 30; error limits are omitted.

Suc-Leu-Leu-Val-Tyr-AMC (Bachem) diluted in buffer B (buffer
A modified to contain 1 mM ATP), and kept at 37 °C for 30 min
on a rocker. Proteasome activity bands were visualized when gels
were exposed to UV (360 nm). Images were collected using a digital
camera.

Results
DMC Caused More Nuclear Shrinkage and DNA
Adducts than MC and Generated Persistent Nuclear
DNA Damage. We previously reported that DMC has increased
cytotoxicity compared to MC in the presence or absence of wildtype p53 with 24 h of drug treatment (33, 34) and have shown
that the frequency of DNA adduct formation in the MCF-7 wildtype p53 breast cancer cell line is higher for DMC than MC
(see Table 1) (30). The predominant stereochemistry of the 1′′mitosene linkage of the DMC adducts to DNA was 1′′-β (2b
and 3b), opposite to the predominant 1′′-R stereochemistry of
the MC adducts (1a, 2a, and 3a) (Figure 1 and Table 1). The
morphology of MCF-7 cells treated with MC for 24 h showed
a barely detectable change in nuclear size as compared to the
untreated cells (Figure 2A and B, MCF-7). However, the MCF-7
cells treated with DMC showed a reproducible and statistically
significant reduction in size as compared to the untreated
population.
To assess if the variable outcome of MC and DMC treatment
of MCF-7 cells was cell type specific and if it occurred in the
absence of wild-type p53, we compared the nuclear morphology
of isogenic colon cancer cells with or without wild-type p53
(DA-2 and DLD-1, respectively) treated with the two drugs
(Figure 2A and B). Analysis of nuclear size as compared to the
untreated cell population supported the hypothesis that DMC
worked through different mechanisms of action than MC,
although the different cell types demonstrated variability in their
nuclear phenotypes following drug treatment. The nuclear
morphology of DA-2 cells treated with MC for 24 h showed a
slight increase in size as compared to the same cells that were
not treated with the drug (Figure 2A and B, DA-2). However,
following 24 h of DMC treatment, DA-2 cells showed a
reproducible and statistically significant reduction in their
nuclear size as compared to their untreated counterpart (Figure
2A and B, DA-2). In the DLD-1 cells that have no functional
p53, MC treatment caused a reproducible and statistically
significant increase in nuclear size, while DMC treatment caused
a reproducible and statistically significant reduction in the
nuclear size. Nuclear shrinkage is often correlated with apoptosis, while swelling is associated with necrosis (43).
We also tested whether the variable outcome of DMC vs MC
in affecting nuclear morphology correlated with a similar greater
potency of DMC to induce damage in the nuclear genome as
well as in the mitochondrial genome in the MCF-7 cell line
(Figure 3A and B). More DNA damage was caused by DMC

than MC to both the mitochondrial genome and the nuclear
genome of MCF-7 cells treated with the drugs for 1 h (Figure
3A and B). Furthermore, the most detectable DMC induced
mitochondrial DNA damage was removed following 12 h
without the drug (Figure 3A), but nuclear DNA adducts caused
by DMC persisted 12 h after drug removal (Figure 3B). These
results do not indicate that MC caused no DNA damage but
rather that under conditions in which DMC caused significant
and persistent DNA damage, MC caused no detectable damage.
The detection limit of this assay is approximately 1 lesion per
105 bases (38).
Chk1 Depletion Following DMC Treatment Can Be
Rescued by Inhibition of the Proteasome. We were specifically interested in the p53-independent mechanism of cell death
induced by DMC and for this reason focused on the DLD-1
cell line for the Chk1 studies. The DLD-1 cell line does not
contain a functional p53 protein. DMC treatment results in the
depletion of Chk1 protein, while MC treatment does not (33).
To determine if the previously identified Chk1 down-regulation
was mediated through a p53-independent ubiquitin-proteasome
pathway, we exposed DLD-1 cells to proteasome inhibitors.
Total ubiquitinated protein products increased when cells were
treated with MG115 (Z-LLnVal) (Figure 4A, compare lanes 1
and 2) or with MG132 (Z-LLLal, data not shown). As expected,
DMC, but not MC, treatment caused the depletion of Chk1
protein (Figure 4A, lanes 3 and 5). However, unexpectedly, the
total ubiquitinated proteins also decreased. Importantly, Chk1
levels and total ubiquitinated proteins were recovered in the
presence of MG115 (Figure 4A, compare lanes 5 and 6). The
recovery of Chk1 upon successful inhibition of the proteasome
pathway implicates the proteasome as the primary mechanism
for Chk1 degradation in DMC treated cells (Figure 4A, lanes 5
and 6). This mechanism of Chk1 regulation in DMC treated
DLD-1 cells, which do not express wild-type p53, was also
observed in DA-2 cells which express wild-type p53 (data not
shown).
DMC DNA Adducts Activate Signaling for Protein
Degradation without Increasing Proteasome Activity. While
Chk1 depletion was clearly facilitated by the ubiquititin proteosome pathway, we had not determined the signaling mechanism associated with its down-regulation. In our current
investigation, we observed concomitant depletion of total
ubiquitinated protein (Figure 4A, lane 5). Increased degradation
of total ubiquitinated protein suggested that perhaps DNA
adducts of DMC signaled for an increase in proteasome activity.
We used an established in-gel assay to detect, in cell lysates,
the cleavage of the fluorogenic peptide substrate Suc-Leu-LeuVal-Tyr-AMC, by the proteasome core particle with both
regulatory particles (RP2CP), core particle with one regulatory
particle (RP1CP), and only the core particle (CP) (42). The
inhibitor, MG115 decreased proteasome activity in DLD-1 cells
(without wild-type p53) (Figure 4B, left panel, lane 2). However,
MC and DMC treatment did not increase proteasome activity
compared to that in the untreated samples (Figure 4B, compare
lanes 3 and 4 to lane 1). The increased degradation of
ubiquitinated substrates in DMC treated cells was not due to a
change in proteasome levels or proteasome activity since DMC
treated and untreated cells showed similar proteasome levels
and activity, respectively (Figure 4B, compare the left panel to
the right panel). The observed decrease in ubiquitinated products
in the absence of an increase in proteasome activity suggested
that DNA adducts of DMC might increase signaling to the
proteolysis machinery.

DNA Adducts Cause Chk1 Depletion by Proteasome
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Figure 2. DMC cytotoxicity is associated with decrease in nuclear size. MCF-7, DA-2, and DLD-1 cells were left untreated or treated for 24 h with
10 µM MC or 10 µM DMC. (A) Representative region of the DAPI stained slide with nuclei from 3 independent experiments is depicted. (B)
Nuclei sizes were determined after staining cells grown on a coverslip with DAPI. Average values obtained from 2 independent experiments are
calculated. For each independent experiment, the number of nuclei measured for each treatment condition was MCF-7 (29); DA-2 (32); and DLD-1
(21). Error bars denote SEM, and the significance was determined using a one-tailed paired t test for the drug treated samples compared to the
untreated controls. P-values of 0.05 or less resulted for DA-2 cells treated with DMC; P-value ) 0.03; DLD-1 cells treated with DMC, P-value )
0.05; and DLD-1 cells treated with MC, P-value ) 0.05. P-value ) paired t test.

To determine if the rescue of Chk1 protein levels by MG115
was due to protein stabilization and not an increase in chk1
RNA, we examined the levels of total chk1 mRNA before and
after the inhibition of the proteasome (Figure 4C). MG115
treatment did not significantly change the levels of the chk1
transcript under any of the test conditions (Figure 4C). DMC
treatment resulted in the reduction of total chk1 mRNA;
however, the rescue in Chk1 protein accumulation seen in Figure
4A was clearly due to a change in Chk1 stability and not mRNA
level as the chk1 mRNA level was not increased upon MG115
treatment.
The chemical composition of the two mitomycin agents is
similar enough that variable toxicity to human cells at equimolar
concentrations, in combination with our previous adduct structure data, suggests that the two drugs possess different modes
of action. However, comparing equimolar versus equitoxic doses
is also important for addressing the question of different
pathways of activation. Because of the high toxicity of DMC,

it was not simple to achieve equal cytotoxicity to MC. We
determined that decreasing the concentration of DMC by 10fold resulted in cytotoxicity comparable to that seen with MC,
resulting in sufficient live cells to examine the biology (Figure
4D). When concentrations of 1 µM to 50 µM of the two agents
were compared for the p53-deficient cells, the cell morphology
and MTT data indicated a similar cytotoxicity of the two drugs
at 1 µM DMC and 10 µM MC (Figure 4D and D′). At these
comparable concentrations, the p53-deficient cells were equally
alive as indicated by mitochondrial activity and matrix attachment. We then asked, how does the signaling of the two agents
compare at these concentrations when very few cells were dead?
Classification of checkpoint pathways is nontrivial, and the
methods used to characterize the cellular changes must be
superimposed on the drug treatment itself. We examined the
cell cycle distribution of the p53-deficient cells as an indicator
of how the two agents influenced the cell cycle populations when
the cells showed similar mitochondrial activity. We found a
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Figure 3. DMC induces more mitochondrial and nuclear DNA damage
than MC. Nuclear and mitochondrial DNA damage was assessed by
QPCR. MCF-7 cells were treated with MC or DMC (10 µM). Cells
were either harvested immediately after treatment (0 h) or allowed to
recover for 12 h. Isolated DNA was subjected to QPCR, and the
amplification of each treated sample was compared to untreated controls
to determine the relative amplification. These values were then used
to calculate the average number of lesions obtained per 10kb of the
genome. Error bars indicate the SEM for triplicate samples.

striking difference in the cell cycle profiles with the two drugs
at equitoxic concentrations (Figure 4D′′). The p53-deficient cells
treated with 1 µM DMC piled up in the S and G2/M stages,
while the 10 µM MC treated cells were found mostly in G1
(Figure 4D′′ FACS). We also examined the Chk1 protein level
in these treated cell populations and found that Chk1 was not
reduced during this early differential cell cycle response (Figure
4E). When the cells were equally alive, the Chk1 levels were
similar, but the cell cycle distribution was very different,
suggesting that a different signaling pathway was engaged. Our
hypothesis is that MC and DMC can mechanistically influence
p53-deficient human cells in different ways and that Chk1
depletion is a later stage event that correlates with cell death.
Depletion of Chk1 by siRNA Increased MC Cytotoxicity,
while Overexpression of Chk1 Slightly Attenuated DMC
Induced Cell Death in the Absence of Wild-Type p53. Since
we observed differential regulation of Chk1 during MC- and

Boamah et al.

DMC- induced cellular cytotoxicity, we hypothesized that the
Chk1 protein might play a role in the differential cytotoxicity
observed for the two drugs. To address this hypothesis, we
depleted the levels of endogenous Chk1 using siRNA and
observed the outcome of drug treatment (Figure 5A, see lanes
7-9). In the absence of Chk1 siRNA, down-regulation of Chk1
protein was only seen in DMC treated cells (Figure 5A, see
lanes 3 and 6). In the presence of Chk1 siRNA, we observed
the dramatic reduction of Chk1 protein in MC treated cells and
investigated if this, as predicted, increased the cytotoxicity of
MC (Figure 5A see lanes 7-9). We observed a statistically
significant decrease in cell proliferation in MC treated samples
when Chk1 was depleted by Chk1 siRNA (Figure 5B, comparing nonspecific siRNA to Chk1-siRNA). Cells that had been
treated with MC showed the most significant decrease in percent
viable cells with siRNA to Chk1 as compared to the nonspecific
siRNA (Figure 5B). Moreover, the cellular cytotoxicity of MC
was not changed when cells were treated with Mdm2 siRNA
used as an unrelated target control. As predicted, Chk1 depletion
increased MC induced death suggesting that any conditions that
reduce the amount of Chk1 also reduce cell viability. The fact
that DMC treatment reduces Chk1, before the addition of Chk1
siRNA, renders the siRNA addition here less significant.
To address the potential of stabilized Chk1 to attenuate DMC
cytotoxicity, we overexpressed a Myc-tagged Chk1 protein,
which was successfully induced under all treatment conditions
(Figure 5C). However, only the endogenous Chk1 protein was
selectively down-regulated by DMC, while the exogenous MycChk1 protein was not (Figure 5C, lane 6). The Myc-tagged Chk1
protein used in our experiments has been reported to induce
phosphorylation of its downstream target Cdc25C in Vitro, but
this exogenous Chk1 has been shown to be less sensitive to
ATR mediated phosphorylation, activation, and proteasome
mediated degradation (44). Treatment with MC did not dramatically influence either endogenous or exogenous Chk1 (Figure
5C, compare lanes 2 and 4). We examined the role of stabilized
Myc-Chk1 in mitomycin induced cellular cytotoxicity (Figure
5C, graph). When exogenous Chk1 was introduced, viability
increased only slightly above the vector control (Figure 5C,
graph). The limited rescue observed may be explained by the
decreased activation for this exogenous Chk1 by the ATR
mediated phosphorylation documented previously. However, the
slight increase in viability observed with the addition of
exogenous Chk1 might be explained by a limited increase in
activation of the G2/M checkpoint.
DMC DNA Adducts Interfere with p53 Transcriptional
Activity. While our studies have focused on the p53-independent
activity of MC and DMC in DLD-1 cells, the possibility existed
that the persistent nuclear DNA damage for 24 h with DMC
might influence wild-type p53 mediated activation of transcription differently than MC. Therefore, the outcome of 24 h
treatment with MC and DMC on DNA damage induced
transcriptional activity of wild-type p53 was assessed in the p53proficient MCF-7 cells and DA-2 cells. Both MC and DMC
treatment stabilized p53 in both cell lines as determined by
Western blot analysis (Figure 6A and B). The stabilized wildtype p53 after 24 h of 10 µM treatment with MC robustly
activated transcription of the p53 target genes mdm2 and p21.
However, following 24 h of 10 µM DMC treatment, the
stabilized p53 resulted in less activation of p21 than MC and
did not result in transactivation of mdm2 (in fact, a decrease
was observed) (Figure 6A and B). The possibility exists that
the increased frequency of DNA adducts by DMC or perhaps
the mitosene-1-β-DNA adduct stereochemistry produced by
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Figure 4. DMC treatment activates a proteasome dependent depletion of Chk1 without increasing proteasome activity. (A) Whole cell extracts
obtained from DLD-1 cells were left untreated (lane 1), treated with 4 µM MG115 (lane 2), 10 µM MC or 10 µM DMC (lanes 3 and 5), and 10
µM MC or 10 µM DMC with 4 µM MG115 (lanes 4 and 6), and were analyzed by Western blotting for Chk1 protein (top panels) and accumulation
of ubiquitinated proteins (bottom panels). Actin was used as a loading control. Numbers at the top of each sample lane on the ubiquitin blot
represent the relative Chk1 protein normalized to actin. (B) Native gel proteasome assay shows no change in proteasome activity. DLD-1 cells were
left untreated (lane 1) and treated with 4 µM MG115 (lane 2), 10 µM MC (lane 3), or 10 µM DMC (lane 4). Extracts were obtained from cells and
analyzed on a native polyacrylamide gel for proteasome activity (left panel) and Western blot for proteasome subunits (right panel). The different
proteasome forms are labeled as RP2CP, RP1CP, or CP. (C) Fold change mRNA levels for chk1 RNA were analyzed by quantitative real-time
reverse transcriptase-polymerase chain reaction PCR (RT-PCR). Results were normalized to untreated samples and actin values. Error bars indicate
the standard deviations of two independent experiments. (D) Phase contrast image of DLD-1 cells treated with MC and DMC as indicated. (D′)
MTT analysis of cells treated with MC or DMC. (D′′) FACS analysis of DLD-1 cells treated with either 1 µM or 10 µM of MC or DMC. (E) Whole
cell extracts obtained from DLD-1 cells treated with either 1 µM or 10 µM of MC or DMC were analyzed by Western blotting for Chk1 protein.
Actin was used as a loading control.
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(34); the decrease seen here could also be due to increased
induction of cell death after 24 h. Nevertheless, the different
outcomes of MC and DMC treatment on p53-proficient cells
and on the p53-pathway are another indication that DMC and
MC can signal to the cellular machinery differently when used
at similar concentrations. When we compared the p53-proficient
MCF-7 cells treated with the two drugs at concentrations ranging
from 1 µM to 50 µM, a 10-fold difference for the cytotoxic
concentration was observed by MTT analysis and visualization
of matrix attachment (Figure 6C and C′). Interestingly, while 1
µM DMC treatment was equally cytotoxic to 10 µM MC, the
p53 stabilization achieved at the two concentrations was
significantly different (Figure 6C′′, compare lanes 3 and 4); 10
µM MC resulted in a more robust stabilization of p53 than 1
µM DMC treatment. In addition, the equal p53 response at the
1 µM dose in the p53-proficient cells clearly showed highly
different cytotoxicity levels for the two drugs (Figure 6C′′, lanes
2 and 3). This is yet another indication that increased cytotoxicity of DMC as compared to MC is through a p53-independent
pathway.

Discussion

Figure 5. Chk1 down-regulation increased MC cytotoxicity in the absence
of wild-type p53. (A) DLD-1 cells were left untransfected or transfected with
25 nM nonspecific siRNA, 25 nM Mdm2 siRNA, or 25 nM Chk1 siRNA for
24 h. After the transfection incubation period, cells were either left untreated
or treated with 10 µM MC or 10 µM DMC for an additional 24 h. Whole cell
extracts were obtained from these cells and analyzed for Chk1 expression.
Actin was used as a loading control. (B) To determine the percent proliferation,
cells were treated as indicated above. MTT solution was added to each sample
and incubated for an additional 2 h. Values were obtained from 3 independent
experiments, and significance was determined for the siRNA treatment as
compared to the drug treated control. P-values below 0.05 were obtained for
all samples treated with siRNA to Chk1. Error bars denote SEM. P-value )
paired t test. (C) For overexpression, cells were transfected with 4 µg of either
empty vector or Myc-Chk1 for 24 h. After the transfection incubation period,
cells were either left untreated or treated with 10 µM MC or 10 µM DMC for
an additional 24 h. Whole cell extracts were obtained from these cells and
analyzed for Chk1 expression. Actin was used as a loading control. To evaluate
the proliferation of cells overexpressing Myc-Chk1 after treatment with MC
or DMC, cells were treated as indicated above. MTT solution was added to
each sample, and cells were incubated for an additional 2 h. Values were
obtained from 3 independent experiments. Error bars denote SEM.

DMC interferes with the ability of the basal transcription
machinery to produce transcripts from the mdm2 gene and
reduced transcription from the p21 gene. We have previously
noted that at early time points (3 and 6 h) after 10 µM MC and
DMC treatment transcription of the p53 target genes is similar

Down-regulation of Chk1 has been described as an alternative
pathway for inducing cell death when the more common
apoptotic pathways have been sabotaged in cancer cells (22, 45).
We observed Chk1 down-regulation and increased cell death,
especially in the absence of a p53 checkpoint, when cells were
treated with DMC (33). Treatment with DMC produces more
mitosene-1-β-DNA adducts than MC (29, 30). DMC is more
cytotoxic than MC (29), and this increased cytotoxicity does
not depend on the function of wild-type p53, which makes DMC
a promising drug for the many cancers that contain mutant p53
(33, 34). In view of the close structural similarity between MC
and DMC, the differences in their biological effects in human
tumor cell cultures were originally unexpected. In this article,
we further characterize these effects and propose to correlate
them with the known structural differences of the DNA adducts,
the amount of adduct formation, and cellular signaling.
Interstrand cross-link (ICL) DNA adducts are the clinically
relevant cytotoxic lesions produced upon exposure to MC and
DMC (29). The intrinsic ability of the cellular machinery to
recognize and excise ICL lesions from the genome and activate
cell death when genomic integrity is beyond repair underlies
the sensitivity of various cell lines to DNA cross-linking (32).
The increased production of mitosene-1-β-DNA adducts following DMC treatment or their persistence in the nuclear
genome might account for the reduction in nuclear size that
correlates with the increased cytotoxicity observed with this
mitomycin derivative. The nature of the mitosene-1-β interstrand
cross-links and how they contribute to cytotoxicity are just
beginning to emerge and will provide useful tools for dissecting
how different DNA adduct structures signal to alternative cell
death pathways. Such information could be useful in the design
of compounds to target cancers containing a compromised p53
pathway. Our model for how DMC-damaged DNA signals
differently from MC-damaged DNA is presented in Figure 6D.
DMC treatment of cells caused a reduction in nuclear size
which is consistent with a number of types of cell death
including mitotic catastrophe and apoptosis (46), while swelling
is associated with necrosis (43). The DLD-1cells do not have
functional p53 and showed nuclear shrinkage with DMC
treatment and swelling with MC treatment. This difference in
morphological outcome when the cells are treated at the same
concentration supports the possibility that the structural differ-
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Figure 6. DMC DNA adducts disrupt p53 transcriptional activity. (A) MCF-7 and (B) DA-2 cells were left untreated (lane 1) or treated for
24 h with 10 µM MC (lane 2) or 10 µM DMC (lane 3). After treatments, whole cell extracts were obtained from cells and analyzed for p53
protein stability. Actin was used as a loading control. For quantitative PCR analysis, cells were left untreated or treated for 24 h with 10 µM
MC or 10 µM DMC. Transcriptional activity of p53 target genes, p21 and mdm2 mRNA, were analyzed by quantitative real-time reverse
transcriptase-polymerase chain reaction PCR (RT-PCR). Results were normalized to untreated samples and actin values. Error bars indicate
the standard deviations of two independent experiments. (C) Phase contrast image of MCF-7 cells treated with MC and DMC as indicated.
(C′) MTT analysis of cells treated with MC or DMC. (C′′) Whole cell extracts obtained from MCF-7 cells treated with either 1 µM or 10
µM of MC or DMC were analyzed by Western blotting for p53 protein. Actin was used as a loading control. (D) Model:DMC treatment
generates increased amounts of the mitosene-1-β DNA adducts, while the MC treatment produces moderate amounts of mitosene-1-R DNA
adducts. The increased DNA adducts produced by DMC after 24 h interfere with p53 transcriptional activity, signal for the rapid depletion
of endogenous Chk1 by the proteasome, which may disrupt the G2/M cell cycle checkpoint and lead to nuclear condensation. The inability
of cells to arrest at the G2/M checkpoint due to the lack of Chk1 potentiates cytotoxicity of DMC. MC DNA adducts activate Chk1, which
may prolong the Intra S and G2 checkpoints, increase nuclear size, and activate p53 transcriptional activity, while blocking replication stress
induced cell death.
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ence of drugs can cause different types of cell death, especially
in the absence of p53 function. We documented previously that
caspase-3 and -9 activation and PARP cleavage are limited in
DMC treated cells lacking p53 (33), but we have not examined
the activation of caspase-2. An alternative apoptotic program,
which requires caspase-2, can be engaged in cells with depleted
Chk1, and this pathway is not affected by p53 loss (47). Our
data demonstrate that Chk1 depletion can increase the extent
of MC induced cell death and is correlated with DMC induced
cell death; but our data do not indicate if the mechanism is
through mitotic catastrophe or a caspase 2-dependent cell death.
It should be noted that micronuclei formation has been reported
as a characteristic of cells undergoing DNA damage induced
mitotic catastrophe (46, 48). The possibility of cytokinesis in
the absence of complete DNA replication due to increased crosslinks and loss of Chk1 dependent checkpoint could account for
the observed micronuclei. While we do not have direct evidence
for this, our confocal microscopy images of DAPI stained nuclei
(Figure 2) show brightly stained condensed nuclear architecture
after the cells were treated with DMC for 24 h.
It is known that ICLs disrupt DNA replication and transcription (32). ICLs are mostly cytotoxic to cells in the S phase,
which are actively replicating, because these aberrant DNA
structures inhibit replication by stalling the polymerase. The
stalled polymerase activates DNA damage response factors and
checkpoint regulators (10). The ability of Chk1 to arrest the
cell cycle has been shown to prolong cell survival after DNA
damage (49, 50). It is shown here that increased production of
mitosene-1-β-DNA adducts by DMC correlates with a signaling
mechanism that results in the down-regulation of Chk1 by the
ubiquitin proteolysis pathway. In the absence of Chk1, DNAdamaged cells can continue through the G2/M checkpoint
eventually causing death. Recently, it was reported that ATR/
Chk1 signaling is highly specific to replication blockers as
opposed to the alternative ATM/Chk2 regulatory pathway
(45, 51). This suggests that the primary pathway activated by
replication blockers to induce recovery from DNA damage and
prolong cell survival is through the ATR/Chk1 pathway. The
regulation of Chk1 we have observed correlates well with the
differential activation of this pathway by MC and DMC.
Sporadically, we see that 24 h treatment of cells with MC results
in increased Chk1 protein levels; however, we never see a
reduction of Chk1 at the 24 h time point (33). We previously
showed that increasing the time of MC treatment to 72 h caused
a reduction in the Chk1 level; here, we show that increasing
the MC concentration by 10-fold (to 100 µM) causes a reduction
in Chk1. Therefore, when the treatment conditions with MC
are pushed to cytotoxic limits we do see a reduction in Chk1
that correlates with cytotoxicity in cells without wild-type p53.
When Chk1 was down-regulated by siRNA, similar cytotoxicity of equimolar MC and DMC was achieved. Consistent with
our current data, Sugiyama et al. reported that disruption of the
Chk1 G2 checkpoint using UCN-01, a Chk1 inhibitor, increased
the cytotoxicity of MC, and this effect was independent of the
wild-type p53 (52). However, overexpressing Chk1 caused only
a slight decrease in the cytotoxicity of the two mitomycins at
24 h post-treatment. The activity of the exogenous Chk1 is
limited, and therefore, the slight increase in viability detected
is most likely due to this fact (44). It is possibile that the
exogenous Chk1 lacked significant kinase activity or that the
lack of upstream or downstream factors that influence Chk1
activity were down-regulated by DMC DNA adduct signaling.
Down-regulation of these factors might render exogenous Chk1
insufficient to significantly affect the cellular outcome after
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overexpression. However, since we observed a slight increase
in survival after Chk1 overexpression, it remains possible that
overexpressed Chk1 could rescue survival but requires additional
factors.
The regulation of Chk1 has been implicated in the response
of cells to replication blockers. Phosphorylation of Chk1 by ATR
at Ser345 as opposed to Ser317 preferentially destabilizes Chk1
by marking it for ubiquitin mediated proteolysis. Chk1 is now
a target for cancer therapy (12, 53). We observed that when
the proteasome activity was inhibited by MG115, Chk1 protein
levels were recovered even when cells were treated with DMC.
Our data support the hypothesis that DMC down-regulates Chk1
by causing increased ubiquitination and subsequent degradation
by the proteasome. Importantly, we saw that this mechanism
of Chk1 down-regulation happened in the absence of increased
proteasome activation. We did not observe any increase in
proteasome activity in DMC treated samples but observed a
decrease in total ubiquitinated protein products upon treatment
with DMC. This supports the hypothesis that DMC DNA
adducts signal for altered protein post-translational modifications
that cause rapid degradation of the tagged polypeptides. This
was substantiated by preliminary protein microarray data
showing that DMC treatment caused a dramatic reduction in
the levels of many proteins on the Sigma Panorama Cell
Signaling antibody array (data not shown).
When we examined the p53 transcriptional activity, we
observed that while both MC and DMC could stabilize p53,
the p53 in 24 h DMC treated cells did not correlate with
increased levels of the mdm2 gene transcript and resulted in
lower p21 transcription than that seen in MC treated cells.
Robust activation of both mdm2 and p21 was evident in MC
treated cells. The reduced p53 transcriptional activity following
DMC treatment may be due to the fact that the persistent DNA
adducts of DMC, over time, negatively influence the transcription machinery. This suggests that even in the presence of wildtype p53 protein, DMC might activate a parallel p53independent pathway because the p53 target genes are not as
robustly turned on by DMC in spite of stabilization of the p53
protein. Inhibition of mdm2 transcription by DNA damage is
not novel, for example, etoposide induced DNA damage has
also been reported to disrupt transcription of the p53 target gene
mdm2 (54). The parallel death pathways of p53 activation and
p53-independent cell death by DMC will require further
investigation.
We observed that DMC induces p53-independent cell death
in cancer cells in a manner that correlated with ubiquitin
mediated degradation of Chk1 in the presence of persistent DNA
damage. We see that Chk1 degradation is correlated with the
predominant formation of mitosene-1-β guanine adducts of
DMC, in contrast to the mitosene-1-R adducts formed with MC.
This alteration of the chirality of the drug linkage to DNA
undoubtedly changes the alignment of DMC adducts, and this
may be related to the basis of the different DNA damage
signaling mechanisms (see model in Figure 6). The alignment
of the MC mitosene-1-R monoadduct and of the 1-R cross-link
in oligonucleotide duplexes has been well characterized (55-57).
The alignment of the mitosene 1-β adducts of DMC have not
been studied yet.
The mitomycins represent a case in which DNA linkage
chirality is proposed to modulate the biological response to DNA
damage. Well-studied precedents of a relationship of DNA
adduct chirality to biological activity exist, most notably the
case of the adducts of racemic anti-7,8-dihydroxy-9,10-epoxy7,8,9,10-tetrahydrobenzo[a]pyrene (anti-BPDE). The highly
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tumorigenic (+)-anti-BPDE enantiomer mostly forms (90%) the
(+)-trans-anti [BP]-N2-dG adduct, while the nontumorigenic
(-)-anti-BPDE enantiomer forms (-)-trans-anti- and (-)-cisanti-[BP]-N2-dG adducts. The latter two adducts are linked to
the N2 atom of dG with chirality opposite to that of the (+)trans-anti-[BP] adduct (58).
The available data of the present investigation do not allow
us to distinguish with certainty whether the observed differential
signaling by MC and DMC is due to the difference in their
adduct frequency (29, 30 see also Table 1) or to intrinsic
structural differences of their adducts critical for signaling. It
will be necessary to compare these effects at equivalent adduct
frequencies. With respect to the first alternative, it is likely that
the more intense DNA alkylating activity of DMC compared
to that of MC in ViVo is facilitated by its lack of the
10′′-carbamoyl group. This group may hinder the attack by MC,
especially of the production of the MC 1′′-β-dG adducts which
are formed generally at very low frequency in ViVo and in Vitro
(29, 30, 59).
In conclusion, hypoxia, which has been shown to protect
cancer cells, was also reported to activate the ATR/Chk1
pathway to increase cell survival and protection against ROS
mediated DNA damage (60, 61). DMC, which has been shown
to have increased DNA adduct formation under hypoxic
conditions (29), can possibly have therapeutic use due to the
ability of its adducts to signal for rapid Chk1 degradation,
thereby counteracting the cancer-protective effects of hypoxia
and should be considered for further investigation into its clinical
relevance as a chemotherapeutic.
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